CD8 expression	Prostate Cancer	CD8 expression	Prostate Cancer	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B
CD8 expression	Melanoma	CD8 expression	Melanoma	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
CD8 expression	Urothelial Cancer	CD8 expression	Urothelial Cancer	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3
CD8 expression	Melanoma	CD8 expression	Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CD8 expression	Melanoma	CD8 expression	Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
CD8 expression	Renal Cell Carcinoma	CD8 expression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CD8 expression	Solid Tumor	CD8 expression	Solid Tumor	TAB004 Sensitive: C3 – Early Trials TAB004 Sensitive : C3	TAB004 Sensitive: C3 – Early Trials TAB004 Sensitive : C3
CD8 expression	Esophageal Squamous Cell Carcinoma	CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3

CD8 expression

Associations